Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study
ObjectiveThe aim of this feasibility study is to evaluate the use of tranexamic acid and its safe use alongside standard therapy in dogs with primary immune thrombocytopenia (ITP).DesignThis is a cohort feasibility study involving 10 dogs diagnosed with primary ITP that received standard therapy for...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Veterinary Science |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2023.946127/full |
| _version_ | 1797865967624126464 |
|---|---|
| author | Gerard Olivares Gerard Olivares Mellora Sharman Rachel Miller Caroline Kisielewicz Mayank Seth |
| author_facet | Gerard Olivares Gerard Olivares Mellora Sharman Rachel Miller Caroline Kisielewicz Mayank Seth |
| author_sort | Gerard Olivares |
| collection | DOAJ |
| description | ObjectiveThe aim of this feasibility study is to evaluate the use of tranexamic acid and its safe use alongside standard therapy in dogs with primary immune thrombocytopenia (ITP).DesignThis is a cohort feasibility study involving 10 dogs diagnosed with primary ITP that received standard therapy for ITP including corticosteroids, a single dose of vincristine, and omeprazole. Dogs were randomly divided into either the control group (n = 6) or the group receiving tranexamic acid (TXA group, n = 4).Key findingsThe mean time from the start of treatment until remission was 5 days in the TXA group and 6 days in the control group (P = 0.69). Two dogs, one in each group, did not achieve remission. Clinical bleeding scores were not significantly different between both groups (p = 0.43), and the median blood volume administered was 37.5 ml/kg for the TXA group and 9.72 ml/kg for the control group (p = 0.084). Three out of the four dogs receiving TXA of 20 mg/kg IV started vomiting within 15 min of administration and were given a reduced dose of 15 or 10 mg/kg IV.ConclusionTranexamic acid did not confer a clinical benefit in this small cohort study and was associated with a high incidence of vomiting. This study provides useful information for the design of future trials in dogs with ITP receiving tranexamic acid including outcome measures and safety. |
| first_indexed | 2024-04-09T23:16:41Z |
| format | Article |
| id | doaj.art-a8633da7c2a541369772e30076f37590 |
| institution | Directory Open Access Journal |
| issn | 2297-1769 |
| language | English |
| last_indexed | 2024-04-09T23:16:41Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Veterinary Science |
| spelling | doaj.art-a8633da7c2a541369772e30076f375902023-03-22T06:07:15ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692023-03-011010.3389/fvets.2023.946127946127Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility studyGerard Olivares0Gerard Olivares1Mellora Sharman2Rachel Miller3Caroline Kisielewicz4Mayank Seth5Department of Small Animal Internal Medicine, Animal Health Trust, Newmarket, Suffolk, United KingdomDepartment of Small Animal Internal Medicine, Eastcott Veterinary Referrals, Part or Linnaeus Veterinary Limited, Swindon, United KingdomDepartment of Small Animal Internal Medicine, Animal Health Trust, Newmarket, Suffolk, United KingdomDepartment of Small Animal Internal Medicine, Dick White Referrals, Cambridgeshire, United KingdomDepartment of Small Animal Internal Medicine, Pride Veterinary Centre, Derby, United KingdomDepartment of Small Animal Internal Medicine, Animal Health Trust, Newmarket, Suffolk, United KingdomObjectiveThe aim of this feasibility study is to evaluate the use of tranexamic acid and its safe use alongside standard therapy in dogs with primary immune thrombocytopenia (ITP).DesignThis is a cohort feasibility study involving 10 dogs diagnosed with primary ITP that received standard therapy for ITP including corticosteroids, a single dose of vincristine, and omeprazole. Dogs were randomly divided into either the control group (n = 6) or the group receiving tranexamic acid (TXA group, n = 4).Key findingsThe mean time from the start of treatment until remission was 5 days in the TXA group and 6 days in the control group (P = 0.69). Two dogs, one in each group, did not achieve remission. Clinical bleeding scores were not significantly different between both groups (p = 0.43), and the median blood volume administered was 37.5 ml/kg for the TXA group and 9.72 ml/kg for the control group (p = 0.084). Three out of the four dogs receiving TXA of 20 mg/kg IV started vomiting within 15 min of administration and were given a reduced dose of 15 or 10 mg/kg IV.ConclusionTranexamic acid did not confer a clinical benefit in this small cohort study and was associated with a high incidence of vomiting. This study provides useful information for the design of future trials in dogs with ITP receiving tranexamic acid including outcome measures and safety.https://www.frontiersin.org/articles/10.3389/fvets.2023.946127/fulltranexamic acidcaninebleeding scoreimmune thrombocytopenia (ITP)antifibrinolytics |
| spellingShingle | Gerard Olivares Gerard Olivares Mellora Sharman Rachel Miller Caroline Kisielewicz Mayank Seth Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study Frontiers in Veterinary Science tranexamic acid canine bleeding score immune thrombocytopenia (ITP) antifibrinolytics |
| title | Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study |
| title_full | Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study |
| title_fullStr | Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study |
| title_full_unstemmed | Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study |
| title_short | Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study |
| title_sort | use of tranexamic acid in dogs with primary immune thrombocytopenia a feasibility study |
| topic | tranexamic acid canine bleeding score immune thrombocytopenia (ITP) antifibrinolytics |
| url | https://www.frontiersin.org/articles/10.3389/fvets.2023.946127/full |
| work_keys_str_mv | AT gerardolivares useoftranexamicacidindogswithprimaryimmunethrombocytopeniaafeasibilitystudy AT gerardolivares useoftranexamicacidindogswithprimaryimmunethrombocytopeniaafeasibilitystudy AT mellorasharman useoftranexamicacidindogswithprimaryimmunethrombocytopeniaafeasibilitystudy AT rachelmiller useoftranexamicacidindogswithprimaryimmunethrombocytopeniaafeasibilitystudy AT carolinekisielewicz useoftranexamicacidindogswithprimaryimmunethrombocytopeniaafeasibilitystudy AT mayankseth useoftranexamicacidindogswithprimaryimmunethrombocytopeniaafeasibilitystudy |